Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

School of Pharmacy : Mechoulam Raphael

Researchers

 Last updated June 2021 - School of Pharmacy

List of Publications

(1) Banerjee S, Sionov RV, Feldman M, Smoum R, Mechoulam R, Steinberg D. Anandamide alters the membrane properties, halts the cell division and prevents drug efflux in multidrug resistant Staphylococcus aureus. Sci Rep 2021;11(1).

(2) Kogan NM, Peters M, Mechoulam R. Cannabinoid Quinones-A Review and Novel Observations. Molecules 2021;26(6).

(3) Rock EM, Limebeer CL, Sullivan MT, DeVuono MV, Lichtman AH, Di Marzo V, et al. N-Oleoylglycine and N-Oleoylalanine Do Not Modify Tolerance to Nociception, Hyperthermia, and Suppression of Activity Produced by Morphine. Front Synaptic Neurosci 2021;13.

(4) Feldman M, Sionov RV, Mechoulam R, Steinberg D. Anti-biofilm activity of cannabidiol against candida albicans. Microorg 2021;9(2):1-17.

(5) Di Bartolomeo M, Stark T, Maurel OM, Iannotti FA, Kuchar M, Ruda-Kucerova J, et al. Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats. Pharmacol Res 2021;164.

(6) Mechoulam R. Foreword. Adv Exp Med Biol 2021;1297:ix-xi.

(7) Mechoulam R. Foreword. Adv Exp Med Biol 2021;1264:ix-xi.

(8) Sionov RV, Feldman M, Smoum R, Mechoulam R, Steinberg D. Anandamide prevents the adhesion of filamentous Candida albicans to cervical epithelial cells. Sci Rep 2020;10(1).

(9) Rock EM, Sullivan MT, Collins SA, Goodman H, Limebeer CL, Mechoulam R, et al. Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews. Psychopharmacology 2020;237(9):2621-2631.

(10) Ayoub SM, Smoum R, Farag M, Atwal H, Collins SA, Rock EM, et al. Oleoyl alanine (HU595): a stable monomethylated oleoyl glycine interferes with acute naloxone precipitated morphine withdrawal in male rats. Psychopharmacology 2020;237(9):2753-2765.

(11) Stark T, Di Bartolomeo M, Di Marco R, Drazanova E, Platania CBM, Iannotti FA, et al. Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochem Pharmacol 2020;177.

(12) Zhu YF, Linher-Melville K, Niazmand MJ, Sharma M, Shahid A, Zhu KL, et al. An evaluation of the anti-hyperalgesic effects of cannabidiolic acid-methyl ester in a preclinical model of peripheral neuropathic pain. Br J Pharmacol 2020;177(12):2712-2725.

(13) Piscitelli F, Guida F, Luongo L, Iannotti FA, Boccella S, Verde R, et al. Protective Effects of N-Oleoylglycine in a Mouse Model of Mild Traumatic Brain Injury. ACS Chem Neurosci 2020;11(8):1117-1128.

(14) Feldman M, Smoum R, Mechoulam R, Steinberg D. Potential combinations of endocannabinoid/ endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus. PLoS ONE 2020;15(4).

(15) Murillo-Rodríguez E, Arankowsky-Sandoval G, Pertwee RG, Parker L, Mechoulam R. Sleep and neurochemical modulation by cannabidiolic acid methyl ester in rats. Brain Res Bull 2020;155:166-173.

(16) Rock EM, Ayoub SM, Limebeer CL, Gene A, Wills KL, DeVuono MV, et al. Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine. Psychopharmacology 2020;237(2):375-384.

(17) Pacher P, Kogan NM, Mechoulam R. Beyond THC and endocannabinoids. Annu Rev Pharmacol Toxicol 2020;60:637-659.

(18) Feldman M, Sionov R, Smoum R, Mechoulam R, Ginsburg I, Steinberg D. Comparative Evaluation of Combinatory Interaction between Endocannabinoid System Compounds and Poly-L-lysine against Streptococcus mutans Growth and Biofilm Formation. BioMed Res Int 2020;2020.

(19) Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. Sci Rep 2019;9(1).

(20) Baraghithy S, Smoum R, Attar-Namdar M, Mechoulam R, Bab I, Tam J. Hu-671, a novel oleoyl serine derivative, exhibits enhanced efficacy in reversing ovariectomy-induced osteoporosis and bone marrow adiposity. Molecules 2019;24(20).

(21) Petrie GN, Wills KL, Piscitelli F, Smoum R, Limebeer CL, Rock EM, et al. Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague–Dawley rats. Psychopharmacology 2019;236(9):2623-2633.

(22) Friedman L, Smoum R, Feldman M, Mechoulam R, Steinberg D. Does the Endocannabinoid Anandamide Affect Bacterial Quorum Sensing, Vitality, and Motility? Cannabis and Cannabinoid Res 2019;4(2):102-109.

(23) Magid L, Heymann S, Elgali M, Avram L, Cohen Y, Liraz-Zaltsman S, et al. Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury. J Neurotrauma 2019;36(11):1836-1846.

(24) Donvito G, Piscitelli F, Muldoon P, Jackson A, Vitale RM, D'Aniello E, et al. N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice. Neuropharmacology 2019;148:320-331.

(25) Shbiro L, Hen-Shoval D, Hazut N, Rapps K, Dar S, Zalsman G, et al. Effects of cannabidiol in males and females in two different rat models of depression. Physiol Behav 2019;201:59-63.

(26) Stark T, Ruda-Kucerova J, Iannotti FA, D'Addario C, Di Marco R, Pekarik V, et al. Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology 2019;146:212-221.

(27) Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Morales-Lara D, Mechoulam R, Drucker-Colín R. Cannabidiol partially blocks the excessive sleepiness in hypocretin-deficient rats: Preliminary data. CNS Neurol Disord Drug Targets 2019;18(9):705-712.

(28) Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Rev Bras Psiquiatr 2019;41(1):9-14.

(29) Baraghithy S, Smoum R, Drori A, Hadar R, Gammal A, Hirsch S, et al. Magel2 Modulates Bone Remodeling and Mass in Prader-Willi Syndrome by Affecting Oleoyl Serine Levels and Activity. J Bone Miner Res 2019;34(1):93-105.

(30) Feldman M, Smoum R, Mechoulam R, Steinberg D. Antimicrobial potential of endocannabinoid and endocannabinoid-like compounds against methicillin-resistant Staphylococcus aureus. Sci Rep 2018;8(1).

(31) Chiurchiù V, Leuti A, Smoum R, Mechoulam R, Maccarrone M. Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes. FASEB J 2018;32(10):5716-5723.

(32) Hen-Shoval D, Amar S, Shbiro L, Smoum R, Haj CG, Mechoulam R, et al. Acute oral cannabidiolic acid methyl ester reduces depression-like behavior in two genetic animal models of depression. Behav Brain Res 2018;351:1-3.

(33) Abuhasira R, Schleider LB-, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med 2018;49:44-50.

(34) Bar-Lev Schleider L, Mechoulam R, Lederman V, Hilou M, Lencovsky O, Betzalel O, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med 2018;49:37-43.

(35) Pertwee RG, Rock EM, Guenther K, Limebeer CL, Stevenson LA, Haj C, et al. Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats. Br J Pharmacol 2018;175(1):100-112.

(36) Večeřa J, Bártová E, Krejčí J, Legartová S, Komůrková D, Rudá-Kučerová J, et al. HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophrenia-like animals. J Cell Physiol 2018;233(1):530-548.

(37) Wang Y, Mukhopadhyay P, Cao Z, Wang H, Feng D, Haskó G, et al. Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. Sci Rep 2017;7(1).

(38) Silva NR, Gomes FV, Fonseca MD, Mechoulam R, Breuer A, Cunha TM, et al. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative. Prog Neuro-Psychopharmacol Biol Psychiatry 2017;79:369-377.

(39) Rock EM, Limebeer CL, Petrie GN, Williams LA, Mechoulam R, Parker LA. Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats. Psychopharmacology 2017;234(14):2207-2217.

(40) Mechoulam R. Foreword. Cannabis sativa L - Bot and Biotechnol 2017:vii-viii.

(41) Mechoulam R. Cannabis and epilepsy. Epilepsy Behav 2017;70:278-279.

(42) Rock EM, Boulet N, Limebeer CL, Mechoulam R, Parker LA. Cannabinoid 2 (CB2) receptor agonism reduces lithium chloride-induced vomiting in Suncus murinus and nausea-induced conditioned gaping in rats. Eur J Pharmacol 2016;786:94-99.

(43) Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, et al. Correction: Fluorinated cannabidiol derivatives: Enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects (PLoS ONE (2016) 11:7 (e0158779) DOI: 10.1371/journal.pone.0158779). PLoS ONE 2016;11(8).

(44) Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, et al. Fluorinated cannabidiol derivatives: Enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects. PLoS ONE 2016;11(7).

(45) Mechoulam R. Cannabis - The Israeli perspective. J Basic Clin Physiol Pharmacol 2016;27(3):181-187.

(46) Juknat A, Kozela E, Kaushansky N, Mechoulam R, Vogel Z. Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol - Studies in BV-2 microglia and encephalitogenic T cells. J Basic Clin Physiol Pharmacol 2016;27(3):289-296.

(47) Mann A, Cohen-Yeshurun A, Trembovler V, Mechoulam R, Shohami E. Are the endocannabinoid-like compounds N-acyl aminoacids neuroprotective after traumatic brain injury? J Basic Clin Physiol Pharmacol 2016;27(3):209-216.

(48) Maslov LN, Khaliulin I, Zhang Y, Krylatov AV, Naryzhnaya NV, Mechoulam R, et al. Prospects for Creation of Cardioprotective Drugs Based on Cannabinoid Receptor Agonists. J Cardiovasc Pharmacol Ther 2016;21(3):262-272.

(49) Shoval G, Shbiro L, Hershkovitz L, Hazut N, Zalsman G, Mechoulam R, et al. Prohedonic effect of cannabidiol in a rat model of depression. Neuropsychobiology 2016;73(2):123-129.

(50) Kozela E, Haj C, Hanuš L, Chourasia M, Shurki A, Juknat A, et al. HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells. Chem Biol Drug Des 2016;87(1):143-153.

(51) Lee W-, Erdelyi K, Matyas C, Mukhopadhyay P, Varga ZV, Liaudet L, et al. Cannabidiol limits T cell–mediated chronic autoimmune myocarditis: Implications to autoimmune disorders and organ transplantation. Mol Med 2016;22:136-146.

(52) Fisher T, Golan H, Schiby G, Prichen S, Smoum R, Moshe I, et al. In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr Oncol 2016;23:S15-S22.

(53) Haj CG, Sumariwalla PF, Hanuš L, Kogan NM, Yektin Z, Mechoulam R, et al. HU-444, a novel, potent anti-inflammatory, nonpsychotropic cannabinoid. J Pharmacol Exp Ther 2015;355(1):66-75.

(54) Yeshurun M, Shpilberg O, Herscovici C, Shargian L, Dreyer J, Peck A, et al. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. Biol Blood Marrow Transplant 2015;21(10):1770-1775.

(55) Mechoulam R. Preface. Endocannabinoids 2015:vii-ix.

(56) Soni D, Smoum R, Breuer A, Mechoulam R, Steinberg D. Effect of the synthetic cannabinoid HU-210 on quorum sensing and on the production of quorum sensing-mediated virulence factors by Vibrio harveyi. BMC Microbiol 2015;15(1).

(57) Smoum R, Baraghithy S, Chourasia M, Breuer A, Mussai N, Attar-Namdar M, et al. CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency. Proc Natl Acad Sci U S A 2015;112(28):8774-8779.

(58) Mann A, Smoum R, Trembovler V, Alexandrovich A, Breuer A, Mechoulam R, et al. Palmitoyl Serine: An Endogenous Neuroprotective Endocannabinoid-Like Entity After Traumatic Brain Injury. J Neuroimmune Pharmacol 2015;10(2):356-363.

(59) Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 2015;36(5):277-296.

(60) Hao E, Mukhopadhyay P, Cao Z, Erdélyi K, Holovac E, Liaudet L, et al. Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. Mol Med 2015;21:38-45.

(61) Mechoulam R. The Endocannabinoid System: A Look Back and Ahead. Handb Exp Pharmacol 2015;231:vii-ix.

(62) Di Marzo V, Piscitelli F, Mechoulam R. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol 2015;203:75-104.

(63) Sticht MA, Jacklin DL, Mechoulam R, Parker LA, Winters BD. Intraperirhinal cortex administration of the synthetic cannabinoid, HU210, disrupts object recognition memory in rats. Neuroreport 2015;26(5):258-262.

(64) Wasserman E, Tam J, Mechoulam R, Zimmer A, Maor G, Bab I. CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Δ9-tetrahydrocannabinol. Ann New York Acad Sci 2015;1335(1):110-119.

(65) Kogan NM, Melamed E, Wasserman E, Raphael B, Breuer A, Stok KS, et al. Cannabidiol, a major non-psychotropic cannabis constituent enhances fracture healing and stimulates lysyl hydroxylase activity in osteoblasts. J Bone Miner Res 2015;30(10):1905-1913.

(66) Mechoulam R. Looking ahead after 50 years of research on cannabinoids. Cannabinoids; 2014. p. 1-15.

(67) Mechoulam R, Hanuš LO, Pertwee R, Howlett AC. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci 2014;15(11):757-764.

(68) Hanuš L, Shohami E, Bab I, Mechoulam R. N-Acyl amino acids and their impact on biological processes. Biofactors 2014;40(4):381-388.

(69) Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A. Preliminary, open-label, pilot study of add-on oral Δ9- tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Invest 2014;34(8):587-591.

(70) Kaminitz A, Barzilay R, Segal H, Taler M, Offen D, Gil-Ad I, et al. Dominant negative DISC1 mutant mice display specific social behaviour deficits and aberration in BDNF and cannabinoid receptor expression. World J Biol Psychiatry 2014;15(1):76-82.

(71) Maslov LN, Lishmanov YB, Oeltgen P, Pei J-, Krylatov AV, Barzakh EI, et al. Effects of preconditioning on coronary perfusion in cardiac ischemia and reperfusion. Neurosci Behav Physiol 2013;43(9):1039-1048.

(72) Maslov LN, Headrick JP, Mechoulam R, Krylatov AV, Lishmanov AY, Barzakh EI, et al. The role of receptor transactivation in the cardioprotective effects of preconditioning and postconditioning. Neurosci Behav Physiol 2013;43(9):1015-1022.

(73) Mechoulam R, Shohami E. HU-211: A cannabinoid neuroprotective agent. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential; 2013. p. 389-398.

(74) Cohen-Yeshurun A, Willner D, Trembovler V, Alexandrovich A, Mechoulam R, Shohami E, et al. N-arachidonoyl-L-serine (AraS) possesses proneurogenic properties in vitro and in vivo after traumatic brain injury. J Cereb Blood Flow Metab 2013;33(8):1242-1250.

(75) Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, et al. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 2013;75(2):323-333.

(76) Mechoulam R, Parker L. Towards a better cannabis drug. Br J Pharmacol 2013;170(7):1363-1364.

(77) Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013;64:21-47.

(78) Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, Mechoulam R, García C. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology 2013;75:155-163.

(79) Limebeer CL, Rock EM, Mechoulam R, Parker LA. The anti-nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex. Br J Pharmacol 2012;167(5):1126-1136.

(80) Mecha M, Torrao AS, Mestre L, Carrillo-Salinas FJ, Mechoulam R, Guaza C. Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death Dis 2012;3(6).

(81) Sticht MA, Long JZ, Rock EM, Limebeer CL, Mechoulam R, Cravatt BF, et al. Inhibition of monoacylglycerol lipase attenuates vomiting in Suncus murinus and 2-arachidonoyl glycerol attenuates nausea in rats. Br J Pharmacol 2012;165(8):2425-2435.

(82) Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, et al. Cannabidiol, a nonpsychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT 1A somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 2012;165(8):2620-2634.

(83) Horváth B, Magid L, Mukhopadhyay P, Bátkai S, Rajesh M, Park O, et al. A new cannabinoid CB 2receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. Br J Pharmacol 2012;165(8):2462-2478.

(84) Maslov LN, Headrick JP, Mechoulam R, Krylatov AV, Lishmanov AI, Barzakh EI, et al. [Role of receptor transactivation in the cardioprotective effects of preconditioning and postconditioning]. Ross Fiziol Zh Im I M Sechenova 2012;98(3):305-317.

(85) Mechoulam R. Cannabis - A valuable drug that deserves better treatment. Mayo Clin Proc 2012;87(2):107-109.

(86) Brown I, Wahle KWJ, Cascio MG, Smoum-Jaouni R, Mechoulam R, Pertwee RG, et al. Omega-3 N-acylethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines. Prostaglandins Leukotrienes Essent Fatty Acids 2011;85(6):305-310.

(87) Bab I, Smoum R, Bradshaw H, Mechoulam R. Skeletal lipidomics: Regulation of bone metabolism by fatty acid amide family. Br J Pharmacol 2011;163(7):1441-1446.

(88) Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R. Endocannabinoids and traumatic brain injury. Br J Pharmacol 2011;163(7):1402-1410.

(89) Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gõmez-Cañas M, Valdeolivas S, et al. Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 2011;163(7):1365-1378.

(90) Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA. Erratum: The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat (Psychopharmacology DOI: 10.1007/s00213-007-0970-1). Psychopharmacology 2011;216(1):149.

(91) Rock EM, Goodwin JM, Limebeer CL, Breuer A, Pertwee RG, Mechoulam R, et al. Interaction between non-psychotropic cannabinoids in marihuana: Effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology 2011;215(3):505-512.

(92) Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to alzheimer's disease. Mol Pharmacol 2011;79(6):964-973.

(93) Lourbopoulos A, Grigoriadis N, Lagoudaki R, Touloumi O, Polyzoidou E, Mavromatis I, et al. Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res 2011;1390:126-141.

(94) Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanchian G, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med 2011;50(10):1368-1381.

(95) Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011;50(2):193-211.

(96) Avraham Y, Grigoriadis NC, Poutahidis T, Vorobiev L, Magen I, Ilan Y, et al. Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. Br J Pharmacol 2011;162(7):1650-1658.

(97) Murillo-Rodríguez E, Palomero-Rivero M, Millán-Aldaco D, Mechoulam R, Drucker-Colín R. Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats. Life Sci 2011;88(11-12):504-511.

(98) Ofek O, Attar-Namdar M, Kram V, Dvir-Ginzberg M, Mechoulam R, Zimmer A, et al. CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res 2011;26(2):308-316.

(99) Mechoulam R, Hanus L. Other cannabinoids. Marijuana and Madness: Second Edition; 2011. p. 17-22.

(100) Di Marzo V, Piscitelli F, Mechoulam R. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol 2011;203:75-104.

(101) Cohen-Yeshurun A, Trembovler V, Alexandrovich A, Ryberg E, Greasley PJ, Mechoulam R, et al. N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis. J Cereb Blood Flow Metab 2011;31(8):1768-1777.

(102) Rajesh M, Mukhopadhyay P, Btkai S, Patel V, Saito K, Matsumoto S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010;56(25):2115-2125.

(103) Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacol Rev 2010;62(4):588-631.

(104) Smoum R, Bar A, Tan B, Milman G, Attar-Namdar M, Ofek O, et al. Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A 2010;107(41):17710-17715.

(105) Pope C, Mechoulam R, Parsons L. Endocannabinoid signaling in neurotoxicity and neuroprotection. Neurotoxicology 2010;31(5):562-571.

(106) Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, et al. Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 2010;31(9):1584-1591.

(107) Mechoulam R. Endocannabinoids and psychiatric disorders: The road ahead. Rev Bras Psiquiatr 2010;32(SUPPL. 1):S5-S6.

(108) Hanuš LO, Mechoulam R. Novel natural and synthetic ligands of the endocannabinoid system. Curr Med Chem 2010;17(14):1341-1359.

(109) Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM. Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT 1A receptor activation. Br J Pharmacol 2010;159(4):950-957.

(110) Moussaieff A, Mechoulam R. Boswellia resin: From religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J Pharm Pharmacol 2009;61(10):1281-1293.

(111) Avraham Y, Grigoriadis NC, Magen I, Poutahidis T, Vorobiav L, Zolotarev O, et al. Capsaicin affects brain function in a model of hepatic encephalopathy associated with fulminant hepatic failure in mice. Br J Pharmacol 2009;158(3):896-906.

(112) Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 2009;51(3):528-534.

(113) Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease. Glia 2009;57(11):1154-1167.

(114) Avraham Y, Zolotarev O, Grigoriadis NC, Pautahidis T, Magen I, Vorobiav L, et al. Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice (American Journal of Gastroenterology (2009) 103, (3047-3056) DOI: 10.1111/j.1572-0241.2008.02155.x). Am J Gastroenterol 2009;104(3):801.

(115) Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30(10):515-527.

(116) Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R. The Nonpsychoactive Cannabis Constituent Cannabidiol Is a Wake-Inducing Agent. Behav Neurosci 2008;122(6):1378-1382.

(117) Patinkin D, Milman G, Breuer A, Fride E, Mechoulam R. Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation. Eur J Pharmacol 2008;595(1-3):1-6.

(118) Galanti G, Fisher T, Kventsel I, Shoham J, Gallily R, Mechoulam R, et al. Δ9-Tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol 2008;47(6):1062-1070.

(119) Magen I, Avraham Y, Berry E, Mechoulam R. Endocannabinoids in liver disease and hepatic encephalopathy. Curr Pharm Des 2008;14(23):2362-2369.

(120) Moussaieff A, Rimmerman N, Bregman T, Straiker A, Felder CC, Shoham S, et al. Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J 2008;22(8):3024-3034.

(121) Moussaieff A, Shein NA, Tsenter J, Grigoriadis S, Simeonidou C, Alexandrovich AG, et al. Incensole acetate: A novel neuroprotective agent isolated from Boswellia carterii. J Cereb Blood Flow Metab 2008;28(7):1341-1352.

(122) Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, et al. A study investigating the acute dose-response effects of 13 mg and 17 mg Δ 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana. J Psychopharmacol 2008;22(4):441-451.

(123) Palazuelos J, Davoust N, Julien B, Hatterer E, Aguado T, Mechoulam R, et al. The CB2 cannabinoid receptor controls myeloid progenitor trafficking: Involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 2008;283(19):13320-13324.

(124) Ronen A, Gershon P, Drobiner H, Rabinovich A, Bar-Hamburger R, Mechoulam R, et al. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev 2008;40(3):926-934.

(125) Bermúdez-Silva FJ, Suárez J, Baixeras E, Cobo N, Bautista D, Cuesta-Muñoz AL, et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008;51(3):476-487.

(126) McHugh D, Tanner C, Mechoulam R, Pertwee RG, Ross RA. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: Evidence for a site distinct from CB1 and CB 2. Mol Pharmacol 2008;73(2):441-450.

(127) Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA. The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology 2008;196(3):389-395.

(128) Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 2008;54(1):244-249.

(129) Avraham Y, Zolotarev O, Grigoriadis NC, Pautahidis T, Magen I, Vorobiav L, et al. Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice. Am J Gastroenterol 2008;103(12):3047-3056.

(130) Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, et al. Brain imaging study of the acute effects of Δ9- tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology 2008;196(1):119-131.

(131) Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 2008;22(1):285-294.

(132) Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci 2007;9(4):413-430.

(133) Durst R, Danenberg H, Gallily R, Mechoulam R, Meir K, Grad E, et al. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol 2007;293(6):H3602-H3607.

(134) Moussaieff A, Shohami E, Kashman Y, Fride E, Schmitz ML, Renner F, et al. Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-κB activation. Mol Pharmacol 2007;72(6):1657-1664.

(135) Mechoulam R. Endocannabinoids: Functional roles and therapeutic opportunities. G Neuropsicofarmacol 2007;29(4):99-101.

(136) Mechoulam R, Peters M, Murillo-Rodriguez E, Hanuš LO. Cannabidiol - Recent advances. Chem Biodiversity 2007;4(8):1678-1692.

(137) Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 2007;26(4):843-851.

(138) Dagon Y, Avraham Y, Ilan Y, Mechoulam R, Berry EM. Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase. FASEB J 2007;21(10):2431-2441.

(139) Kogan NM, Schlesinger M, Peters M, Marincheva G, Beeri R, Mechoulam R. A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: A comparative in vivo study. J Pharmacol Exp Ther 2007;322(2):646-653.

(140) Dagon Y, Avraham Y, Link G, Zolotarev O, Mechoulam R, Berry EM. The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells. Neurobiol Dis 2007;27(2):174-181.

(141) Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007;316(5830):1494-1497.

(142) García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 2007;1134(1):162-170.

(143) Hanuš L, Mechoulam R. Plant and brain Cannabinoids: The chemistry of major new players in physiology. Selected Topics in the Chemistry of Natural Products; 2007. p. 49-75.

(144) Mechoulam R, Shohami E. Endocannabinoids and traumatic brain injury. Mol Neurobiol 2007;36(1):68-74.

(145) Kogan NM, Schlesinger M, Priel E, Rabinowitz R, Berenshtein E, Chevion M, et al. HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol Cancer Ther 2007;6(1):173-183.

(146) Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzmán M, Galve-Roperh I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 2006;20(13):E1773-E1779.

(147) Mccarron RM, Chen Y, Tomori T, Strasser A, Mechoulam R, Shohami E, et al. Endothelial-mediated regulation of cerebral microcirculation. J Physiol Pharmacol 2006;57(SUPPL. 11):133-144.

(148) Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett 2006;580(18):4337-4345.

(149) Kogan NM, Blázquez C, Álvarez L, Gallily R, Schlesinger M, Guzmán M, et al. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol 2006;70(1):51-59.

(150) Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 2006;22(2):257-264.

(151) Mechoulam R, Berry EM, Avraham Y, Di Marzo V, Fride E. Endocannabinoids, feeding and suckling - From our perspective. Int J Obes 2006;30(SUPPL. 1):S24-S28.

(152) Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006;39(2):143-151.

(153) Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, et al. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A 2006;103(7):2428-2433.

(154) Parker LA, Kwiatkowska M, Mechoulam R. Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting. Physiol Behav 2006;87(1):66-71.

(155) Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 2006;103(3):696-701.

(156) Kogan NM, Mechoulam R. The chemistry of endocannabinoids. J Endocrinol Invest 2006;29(3 Suppl):3-14.

(157) Tam J, Ofek O, Fride E, Ledent C, Gabet Y, M̈uller R, et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 2006;70(3):786-792.

(158) Avraham Y, Israeli E, Gabbay E, Okun A, Zolotarev O, Silberman I, et al. Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. Neurobiol Dis 2006;21(1):237-245.

(159) Mechoulam R, Deutsch DG. Toward an anandamide transporter. Proc Natl Acad Sci U S A 2005;102(49):17541-17542.

(160) Mechoulam R. Preface. Handb Exp Pharmacol 2005;168:VII-VIII.

(161) Mechoulam R. Plant cannabinoids: A neglected pharmacological treasure trove. Br J Pharmacol 2005;146(7):913-915.

(162) Moussaieff A, Fride E, Amar Z, Lev E, Steinberg D, Gallily R, et al. The Jerusalem Balsam: From the Franciscan Monastery in the old city of Jerusalem to Martindale 33. J Ethnopharmacol 2005;101(1-3):16-26.

(163) Unzicker C, Erberich H, Moldrich G, Woldt H, Bulla J, Mechoulam R, et al. Hippocampal cannabinoid-1 receptor upregulation upon endothelin-B receptor deficiency: A neuroprotective substitution effect? Neurochem Res 2005;30(10):1305-1309.

(164) Fride E, Suris R, Weidenfeld J, Mechoulam R. Differential response to acute and repeated stress in cannabinoid CB 1 receptor knockout newborn and adult mice. Behav Pharmacol 2005;16(5-6):431-440.

(165) Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E. CB1 cannabinoid receptors are involved in neuroprotection via NF-κB inhibition. J Cereb Blood Flow Metab 2005;25(4):477-484.

(166) Hanuš LO, Tchilibon S, Ponde DE, Breuer A, Fride E, Mechoulam R. Enantiomeric cannabidiol derivatives: Synthesis and binding to cannabinoid receptors. Org Biomol Chem 2005;3(6):1116-1123.

(167) Avraham Y, Menachem AB, Okun A, Zlotarav O, Abel N, Mechoulam R, et al. Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. Brain Res Bull 2005;65(2):117-123.

(168) Sarne Y, Mechoulam R. Cannabinoids: Between neuroprotection and neurotoxicity. Curr Drug Targets: CNS Neurol Disord 2005;4(6):677-684.

(169) Makriyannis A, Mechoulam R, Piomelli D. Therapeutic opportunities through modulation of the endocannabinoid system. Neuropharmacology 2005;48(8 SPEC. ISS.):1068-1071.

(170) Mechoulam R, Sumariwalla PF, Feldmann M, Gallily R. Cannabinoids in models of chronic inflammatory conditions. Phytochem Rev 2005;4(1):11-18.

(171) Pertwee RG, Thomas A, Stevenson LA, Maor Y, Mechoulam R. Evidence that (-)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferens. Neuropharmacology 2005;48(8 SPEC. ISS.):1139-1146.

(172) Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiol Dis 2005;19(1-2):96-107.

(173) Maccarrone M, Fride E, Bisogno T, Bari M, Cascio MG, Battista N, et al. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Mol Hum Reprod 2005;11(1):21-28.

(174) Fride E, Feigin C, Ponde DE, Breuer A, Hanuš L, Arshavsky N, et al. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur J Pharmacol 2004;506(2):179-188.

(175) Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, et al. Human brain endothelium: Coexpression and function of vanilloid and endocannabinoid receptors. Mol Brain Res 2004;132(1):87-92.

(176) Navab R, Aingorn H, Fallavollita L, Sallon S, Mechoulam R, Ginsburg I, et al. PADMA-28, a traditional Tibetan herbal preparation, blocks cellular responses to bFGF and IGF-I. Inflammopharmacology 2004;12(4):373-389.

(177) Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R. Effect of low doses of Δ9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology 2004;175(3):360-366.

(178) Kogan NM, Rabinowitz R, Levi P, Gibson D, Sandor P, Schlesinger M, et al. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem 2004;47(15):3800-3806.

(179) Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A Novel Synthetic, Nonpsychoactive Cannabinoid Acid (HU-320) with Antiinflammatory Properties in Murine Collagen-Induced Arthritis. Arthritis Rheum 2004;50(3):985-998.

(180) Mechoulam R. The promise of advances in the field of endocannabinoids. Neuro Endocrinol Lett 2004;25(1-2):11-12.

(181) Kwiatkowska M, Parker LA, Burton P, Mechoulam R. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 2004;174(2):254-259.

(182) Parker LA, Kwiatkowska M, Burton P, Mechoulam R. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 2004;171(2):156-161.

(183) Burstein S, Zurier RB, Sumariwalla PF, Feldmann M, Gallily R, Mechoulam R, et al. Pain reduction and lack of psychotropic effects with ajulemic acid: Comment on the article by Sumariwalla et al [4] (multiple letters). Arthritis Rheum 2004;50(12):4078-4079.

(184) Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E. Cannabidiol - Transdermal delivery and anti-inflammatory effect in a murine model. J Control Release 2003;93(3):377-387.

(185) Mechoulam R, Lichtman AH. Stout guards of the central nervous system. Science 2003;302(5642).

(186) Gallily R, Even-Chen T, Katzavian G, Lehmann D, Dagan A, Mechoulam R. γ-Irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma 2003;44(10):1767-1773.

(187) Hanuš L, Avraham Y, Ben-Shushan D, Zolotarev O, Berry EM, Mechoulam R. Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Res 2003;983(1-2):144-151.

(188) Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacol Toxicol 2003;93(2):66-70.

(189) Leker RR, Gai N, Mechoulam R, Ovadia H. Drug-induced hypothermia reduces ischemic damage: Effects of the cannabinoid HU-210. Stroke 2003;34(8):2000-2006.

(190) Mechoulam R, Parker L. Cannabis and alcohol - A close friendship. Trends Pharmacol Sci 2003;24(6):266-268.

(191) Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: Evidence for a "CB3" receptor. Eur J Pharmacol 2003;461(1):27-34.

(192) Parker LA, Mechoulam R. Cannabinoid Agonists and Antagonists Modulate Lithium-induced Conditioned Gaping in Rats. Integr Physiol Behav Sci 2003;38(2):133-145.

(193) Parker LA, Mechoulam R, Schlievert C, Abbott L, Fudge ML, Burton P. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology 2003;166(2):156-162.

(194) Spatz M, McCarron RM, Shohami E, Panikashvili D, Chen Y, Golcch S, et al. Antioxidant properties of the vasoactive endocannabinoid, 2-arachidonoyl glycerol (2-AG). Acta Neurochir Suppl 2003(86):271-275.

(195) Mechoulam R, Hanuš L. Cannabidiol: An overview of some chemical and pharmacological aspects. Part I: Chemical aspects. Chem Phys Lipids 2002;121(1-2):35-43.

(196) Mechoulam R, Parker LA, Gallily R. Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol 2002;42(11 SUPPL.):11S-19S.

(197) Laine K, Järvinen K, Mechoulam R, Breuer A, Järvinen T. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci 2002;43(10):3216-3222.

(198) Ugdyzhekova DS, Krylatov AV, Bernatskaya NA, Maslov LN, Mechoulam R, Pertwee RG. Activation of cannabinoid receptors decreases the area of ischemic myocardial necrosis. Bull Exp Biol Med 2002;133(2):125-126.

(199) Krylatov AV, Uzhachenko RV, Maslov LN, Bernatskaya NA, Makriyannis A, Mechoulam R, et al. Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: A possible mechanism. Bull Exp Biol Med 2002;133(2):122-124.

(200) Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54(2):161-202.

(201) Parker LA, Mechoulam R, Schlievert C. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002;13(5):567-570.

(202) Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V. Noladin ether, a putative novel endocannabinoid: Inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett 2002;513(2-3):294-298.

(203) Mechoulam R. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukotrienes Essent Fatty Acids 2002;66(2-3):93-99.

(204) Berry EM, Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002;95(2):185-190.

(205) Mechoulam R, Spatz M, Shohami E. Endocannabinoids and neuroprotection. Sci STKE 2002;2002(129).

(206) Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: Therapeutic implications. Trends Mol Med 2002;8(2):58-61.

(207) Krylatov AV, Bernatskaia NA, Maslov LN, Pertwee RG, Mechoulam R, Stefano GB, et al. Increase of the heart arrhythmogenic resistance and decrease of the myocardial necrosis zone during activation of cannabinoid receptors. Ross Fiziol Zh Im I M Sechenova 2002;88(5):560-567.

(208) Panikashvili D, Simeonidou C, Ben-Shabat S, Hanuš L, Breuer A, Mechoulam R, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001;413(6855):527-531.

(209) Rubnov S, Kashman Y, Rabinowitz R, Schlesinger M, Mechoulam R. Suppressors of cancer cell proliferation from fig (Ficus carica) resin: Isolation and structure elucidation. J Nat Prod 2001;64(7):993-996.

(210) Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V, Mechoulam R. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 2001;419(2-3):207-214.

(211) Mechoulam R, Fride E. Physiology: A hunger for cannabinoids. Nature 2001;410(6830):763-765.

(212) Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001;98(7):3662-3665.

(213) Mechoulam R, Hanuš L. The cannabinoids: An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manage 2001;6(2):67-73.

(214) Crozier Willi G, Berger A, Di Marzo V, Bisogno T, De Petrocellis L, Fride E, et al. Lipids in neural function: modulation of behavior by oral administration of endocannabinoids found in foods. Nestle Nutr Workshop Ser Clin Perform Programme 2001;5:169-184; discussion 185-187.

(215) Bisogno T, Hanuš L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134(4):845-852.

(216) Mechoulam R, Hanuš L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids 2000;108(1-2):1-13.

(217) Tchilibon S, Mechoulam R. Synthesis of a primary metabolite of cannabidiol. Org Lett 2000;2(21):3301-3303.

(218) Gallily R, Breuer A, Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-α production in murine macrophages, and in mice. Eur J Pharmacol 2000;406(1):R5-R7.

(219) Chen Y, McCarron RM, Ohara Y, Bembry J, Azzam N, Lenz FA, et al. Human brain capillary endothelium: 2-Arachidonoglycerol (endocannabinoid) interacts with endothelin-1. Circ Res 2000;87(4):323-327.

(220) Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000;97(17):9561-9566.

(221) Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000;392(3):147-156.

(222) Mechoulam R. Looking back at cannabis research. Curr Pharm Des 2000;6(13):1313-1322.

(223) Shohami E, Mechoulam R. Dexanabinol (HU-211): A nonpsychotropic cannabinoid with neuroprotective properties. Drug Dev Res 2000;50(3-4):211-215.

(224) Ugdyzhekova DS, Davydova YG, Maimeskulova LA, Mechoulam R. Involvement of central and peripheral cannabinoid receptors in the regulation of heart resistance to arrhythmogenic effects of epinephrine. Bull Exp Biol Med 2000;130(11):1087-1089.

(225) Naveh N, Weissman C, Muchtar S, Benita S, Mechoulam R. A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefe's Arch Clin Exp Ophthalmol 2000;238(4):334-338.

(226) Mechoulam R. Recent advances in Cannabinoid research. Forsch Komplementarmed 1999;6(SUPPL. 3):16-20.

(227) Hanuš L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A 1999;96(25):14228-14233.

(228) Martin BR, Mechoulam R, Razdan RK. Discovery and characterization of endogenous cannabinoids. Life Sci 1999;65(6-7):573-595.

(229) Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: The ongoing story of cannabis. Nat Prod Rep 1999;16(2):131-143.

(230) Ginsburg I, Sadovnik M, Sallon S, Milo-Goldzweig I, Mechoulam R, Breuer A, et al. PADMA-28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids. Inflammopharmacology 1999;7(1):47-62.

(231) Di Marzo V, Sepe N, De Petrocellis L, Berger A, Crozier G, Fride E, et al. Trick or treat from food endocannabinoids? [4] (multiple letters). Nature 1998;396(6712):636-637.

(232) Mechoulam R, Fride E, Ben-Shabat S, Meiri U, Horowitz M. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol 1998;362(1):R1-R3.

(233) Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol 1998;359(1):1-18.

(234) Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee M-, Vogel Z, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 1998;353(1):23-31.

(235) Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998;59(2):347-352.

(236) Mechoulam R, Golan D. Comment on ‘Health aspects of cannabis: Revisited’ (Hollister). Int J Neuropsychopharmacol 1998;1(1):83-85.

(237) Mechoulam R, Hanuš L, Fride E. 5 Towards cannabinoid drugs - revisited. Prog Med Chem 1998;35(C):199-243.

(238) Gallily R, Yamin A, Waksmann Y, Ovadia H, Weidenfeld J, Bar-Joseph A, et al. Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 1997;283(2):918-924.

(239) Bisogno T, Sepe N, De Petrocellis L, Mechoulam R, Di Marzo V. The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun 1997;239(2):473-479.

(240) Rhee M-, Vogel Z, Barg J, Bayewitch M, Levy R, Hanuš L, et al. Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 1997;40(20):3228-3233.

(241) Sheskin T, Hanuš L, Slager J, Vogel Z, Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 1997;40(5):659-667.

(242) Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T. Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J Neuroimmunol 1997;72(2):169-177.

(243) Mechoulam R. Todd's achievement [6]. Nature 1997;386(6627):755.

(244) Mechoulam R, Fride E, Hanuš L, Sheskin T, Bisogno T, Marzo VD, et al. Anandamide may mediate sleep induction [6]. Nature 1997;389(6646):25-26.

(245) Shohami E, Weidenfeld J, Ovadia H, Vogel Z, Hanuš L, Fride E, et al. Endogenous and synthetic cannabinoids: Recent advances. CNS Drug Rev 1996;2(4):429-451.

(246) Fride E, Mechoulam R. Ontogenetic development of the response to anandamide and Δ9-tetrahydrocannabinol in mice. Dev Brain Res 1996;95(1):131-134.

(247) Bayewitch M, Rhee M-, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z. (-)-Δ9-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 1996;271(17):9902-9905.

(248) Pop E, Soti F, Brewster ME, Barenholz Y, Korablyov V, Mechoulam R, et al. Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water-solubility. Pharm Res 1996;13(3):469-475.

(249) Pop E, Liu ZZ, Brewster ME, Barenholz Y, Korablyov V, Mechoulam R, et al. Derivatives of dexanabinol. I. Water-soluble salts of glycinate esters. Pharm Res 1996;13(1):62-69.

(250) Fride E, Mechoulam R. Developmental aspects of anandamide: Ontogeny of response and prenatal exposure. Psychoneuroendocrinology 1996;21(2):157-172.

(251) Wilson Jr. RG, Tahir SK, Mechoulam R, Zimmerman S, Zimmerman AM. Cannabinoid enantiomer action on the cytoarchitecture. Cell Biol Int 1996;20(2):147-157.

(252) Mechoulam R, Ben Shabat S, Hanuš L, Fride E, Bayewitch M, Vogel Z. Endogenous cannabinoid ligands. ADV EXP MED BIOL 1996;402:95-100.

(253) Mechoulam R, Ben Shabat S, Hanuš L, Fride E, Vogel Z, Bayewitch M, et al. Endogenous cannabinoid ligands - Chemical and biological studies. J LIPID MEDIATORS CELL SIGNAL 1996;14(1-3):45-49.

(254) Barg J, Fride E, Hanus L, Levy R, Matus-Leibovitch N, Heldman E, et al. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur J Pharmacol 1995;287(2):145-152.

(255) Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 1995;375(1-2):143-147.

(256) Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50(1):83-90.

(257) Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 1995;56(23-24):2097-2102.

(258) Ovadia H, Wohlman A, Mechoulam R, Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 1995;34(2):1725-175.

(259) Ovadia H, Wohlman A, Mechoulam R, Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 1995;34(2):175-180.

(260) Taura F, Morimoto S, Shoyama Y, Mechoulam R. First Direct Evidence for the Mechanism of Δ1-Tetrahydrocannabinolie Acid Biosynthesis. J Am Chem Soc 1995;117(38):9766-9767.

(261) Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol [3]. J Clin Psychiatry 1995;56(10):485-486.

(262) Fride E, Barg J, Levy R, Saya D, Heldman E, Mechoulam R, et al. Low doses of anandamides inhibit pharmacological effects of Δ9- tetrahydrocannabinol. J Pharmacol Exp Ther 1995;272(2):699-707.

(263) Glaser R, Adin I, Mechoulam R, Hanuš L. 2-Methyl- and 4-methyl-δ8-tetrahydrocannabinol: Correlation of spatial distinction with cannabinoid receptor binding. Heterocycles 1994;39(2):867-877.

(264) Martin BR, Childers S, Howlett A, Mechoulam R, Pertwee R. Cannabinoid receptors: Pharmacology, second messenger systems and endogenous ligands. NIDA RES MONOGR SER 1994(140):55-60.

(265) Vogel Z, Bayewitch M, Levy R, Matus-Leibovitch N, Hanus L, Ben-Shabat S, et al. Binding and functional studies with the peripheral and neuronal cannabinoid receptors. Regul Pept 1994;54(1):313-314.

(266) Mechoulam R, Hanuš L, Martin BR. Search for endogenous ligands of the cannabinoid receptor. Biochem Pharmacol 1994;48(8):1537-1544.

(267) Schuel H, Goldstein E, Mechoulam R, Zimmerman AM, Zimmerman S. Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl Acad Sci U S A 1994;91(16):7678-7682.

(268) Pertwee R, Griffin G, Hanuš L, Mechoulam R. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur J Pharmacol 1994;259(2):115-120.

(269) Abu-Lafi S, Sterin M, Levin S, Mechoulam R. Structural features affecting chiral discrimination of terpene derivatives, on a carbamated amylose stationary phase. J Chromatogr A 1994;664(2):159-167.

(270) Mechoulam R. Cannabis chemistry, biochemistry, toxicology and therapeutic applications. JPN J FORENSIC TOXICOL 1994;12(2):76-83.

(271) Weidenfeld J, Feldman S, Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 1994;59(2):110-112.

(272) Järbe TUC, Mechoulam R, Zahalka J. Discriminative stimulus- and open-field effects of the enantiomers of 11-hydroxy-delta-8-tetrahydrocannabinol in pigeons and gerbils. Pharmacol Biochem Behav 1994;47(1):113-119.

(273) Mechoulam R, Vogel Z, Barg J. CNS Cannabinoid Receptors: Role and Therapeutic Implications for CNS Disorders. CNS Drugs 1994;2(4):255-260.

(274) Rodríguez De Fonseca F, Martín Calderón JL, Mechoulam R, Navarro M. Repeated stimulation of D1 dopamine receptors enhances (-)-11-hydroxy-Δ8-tetrahydrocannabinol-dimethylheptyl-induced catalepsy in male rats. Neuroreport 1994;5(7):761-765.

(275) Guimarães FS, Aguiar JCd, Mechoulam R, Breuer A. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol Vasc Syst 1994;25(1):161-164.

(276) Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994;270(1):219-227.

(277) Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T. Suppression of experimetal autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 1994;28(3):209-214.

(278) Jarbe TUC, Hiltunen AJ, Mathis DA, Hanus L, Breuer A, Mechoulam R. Discriminative stimulus effects and receptor binding of enantiomeric pairs of cannabinoids in rats and pigeons; A comparison. J Pharmacol Exp Ther 1993;264(2):561-569.

(279) Nadler V, Mechoulam R, Sokolovsky M. The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-Δ6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-d-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci Lett 1993;162(1-2):43-45.

(280) Levin S, Abu-Lafi S, Zahalka J, Mechoulam R. Resolution of chiral cannabinoids on amylose tris(3,5-dimethylphenylcarbamate) chiral stationary phase: Effects of structural features and mobile phase additives. J Chromatogr A 1993;654(1):53-64.

(281) Nadler V, Mechoulam R, Sokolovsky M. Blockade of 45Ca2+ influx through the N-methyl-d-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211. Brain Res 1993;622(1-2):79-85.

(282) Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993;231(2):313-314.

(283) Shohami E, Novikov M, Mechoulam R. A Nonpsychotropic Cannabinoid, HU-211, Has Cerebroprotective Effects After Closed Head Injury in the Rat. J Neurotrauma 1993;10(2):109-119.

(284) Hanuš L, Gopher A, Almog S, Mechoulam R. Two New Unsaturated Fatty Acid Ethanolamides in Brain That Bind to the Cannabinoid Receptor. J Med Chem 1993;36(20):3032-3034.

(285) Martin BR, Cabral G, Childers SR, Deadwyler S, Mechoulam R, Reggio P. International Cannabis Research Society Meeting Summary, Keystone, CO (June 19-20, 1992). Drug Alcohol Depend 1993;31(3):219-227.

(286) Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R. Anandamide, a Brain Endogenous Compound, Interacts Specifically with Cannabinoid Receptors and Inhibits Adenylate Cyclase. J Neurochem 1993;61(1):352-355.

(287) Zlas J, Stark H, Seligman J, Levy R, Werker E, Breuer A, et al. Early medical use of cannabis [5]. Nature 1993;363(6426):215.

(288) Burstein SH, Audette CA, Doyle SA, Breuer A, Devane WA, Colodner S, et al. Synthetic Nonpsychotropic Cannabinoids with Potent Antiinflammatory, Analgesic, and Leukocyte Antiadhesion Activities. J Med Chem 1992;35(17):3135-3141.

(289) Devane WA, Breuer A, Sheskin T, Järbe TUC, Eisen MS, Mechoulam R, et al. A Novel Probe for the Cannabinoid Receptor. J Med Chem 1992;35(11):2065-2069.

(290) Nathan I, Agam G, Mechoulam R, Dvilansky A, Livne AA. Effect of synthetic enantiomeric cannabinoids on platelet aggregation. Can J Physiol Pharmacol 1992;70(10):1305-1308.

(291) Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea‐pig small intestine. Br J Pharmacol 1992;105(4):980-984.

(292) Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258(5090):1946-1949.

(293) Harvey DJ, Samara E, Mechoulam R. Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 1991;562(1-2):299-322.

(294) Harvey DJ, Samara E, Mechoulam R. Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem Behav 1991;40(3):523-532.

(295) Mechoulam R, Breuer A, Feigenbaum JJ, Devane WA. Nonpsychotropic synthetic cannabinoids as therapeutic agents. Farmaco 1991;46(SUPPL. 1):267-276.

(296) Zimmerman AM, Titishov N, Mechoulam R, Zimmerman S. Effect of stereospecific cannabinoids on the immune system. ADV EXP MED BIOL 1991;288:71-80.

(297) Mechoulam R, Devane WA, Breuer A, Zahalka J. A random walk through a cannabis field. Pharmacol Biochem Behav 1991;40(3):461-464.

(298) Zeltser R, Seltzer Z, Eisen A, Feigenbaum JJ, Mechoulam R. Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties. Pain 1991;47(1):95-103.

(299) Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 1991;40(3):471-478.

(300) Harvey DJ, Mechoulam R. Metabolites of cannabidiol identified in human urine. Xenobiotica 1990;20(3):303-320.

(301) Howlett AC, Champion TM, Wilken GH, Mechoulam R. Stereochemical effects of 11-OH-Δ8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology 1990;29(2):161-165.

(302) Mechoulam R, Lander N, University A, Zahalka J. Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative. Tetrahedron Asymmetry 1990;1(5):315-318.

(303) Mechoulam R, Breuer A, Järbe TUC, Hiltunen AJ, Glaser R. Cannabimimetic Activity of Novel Enantiomeric, Benzofuran Cannabinoids. J Med Chem 1990;33(3):1037-1043.

(304) Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci U S A 1989;86(23):9584-9587.

(305) Feigenbaum JJ, Richmond SA, Weissman Y, Mechoulam R. Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. Eur J Pharmacol 1989;169(1):159-165.

(306) Mechoulam R. Alkaloids in Cannabis Sativa L. Alkaloids Chem Pharmacol 1989;34(C):77-93.

(307) Titishov N, Mechoulam R, Zimmerman AM. Stereospecific effects of (-)- and (+)-7-hydroxy-delta-6-tetrahydrocannabinol-dimethylheptyi on the immune system of mice. Pharmacology 1989;39(6):337-349.

(308) Jarbe TUC, Hiltunen AJ, Mechoulam R. Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-Δ8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exp Ther 1989;250(3):1000-1005.

(309) Järbe TUC, Hiltunen AJ, Mechoulam R. Subjectively experienced cannabis effects in animals. Drug Dev Res 1989;16(2-4):385-393.

(310) Little PJ, Compton DR, Mechoulam R, Martin BR. Stereochemical effects of 11-OH-Δ8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav 1989;32(3):661-666.

(311) Järbe TUC, Hiltunen AJ, Mechoulam R, Srebnik M, Breuer A. Separation of the discriminative stimulus effects of stereoisomers of Δ2- and Δ3-tetrahydrocannabinols in pigeons. Eur J Pharmacol 1988;156(3):361-366.

(312) Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Järbe TUC, Hiltunen AJ, et al. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 1988;44(9):762-764.

(313) Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos 1988;16(3):469-472.

(314) Hollister LE, Gillespie HK, Mechoulam R, Srebnik M. Human pharmacology of 1S and 1R enantiomers of delta-3-tetrahydrocannabinol. Psychopharmacology 1987;92(4):505-507.

(315) Mechoulam R, Feigenbaum JJ. Towards cannabinoid drugs. Prog Med Chem 1987;24(C):159-207.

(316) Consroe P, Mechoulam R. Anticonvulsant and neurotoxic effects of tetrahydrocannabinol stereoisomers. NIDA Res Monogr 1987;79:59-66.

(317) Srebnik M, Mechoulam R, Yona I. Halogenation of phenols and phenyl ethers with potassium halides in the presence of 18-crown-6 on oxidation with m-chloroperbenzoic acid. Journal of the Chemical Society, Perkin Transactions 1 1987:1423-1427.

(318) Yocum LB, Denlinger DL, Katlic NE, Brueggemeier RW, Mechoulam R. A developmental profile of estrogen and androgen radioimmunoactive substances in the flesh fly, Sarcophaga crassipalpis. Insect Biochemistry 1987;17(8):1149-1153.

(319) Martin AR, Consroe P, Kane VV, Shah V, Singh V, Lander N, et al. Structure-anticonvulsant activity relationships of cannabidiol analogs. NIDA Res Monogr 1987;79:48-58.

(320) Mechoulam R, Lander N, Srebnik M, Breuer A, Segal M, Feigenbaum JJ, et al. Stereochemical requirements for cannabimimetic activity. NIDA Res Monogr 1987;79:15-30.

(321) Burstein S, Hunter SA, Latham V, Mechoulam R, Melchior DL, Renzulli L, et al. Prostaglandins and cannabis XV. Comparison of enantiomeric cannabinoids in stimulating prostaglandin synthesis in fibroblasts. Life Sci 1986;39(19):1813-1823.

(322) Mechoulam R. Interview with Prof. Raphael mechoulam, codiscoverer of THC. Subst Use Misuse 1986;21(4-5):579-587.

(323) Järbe TUC, Hiltunen AJ, Lander N, Mechoulam R. Cannabimimetic activity (Δ1-THC cue) of cannabidiol monomethyl ether and two stereoisomeric hexahydrocannabinols in rats and pigeons. Pharmacol Biochem Behav 1986;25(2):393-399.

(324) Baek S-, Srebnik M, Mechoulam R. Boron triflouride etherate on alimina - a modified Lewis acid reagent. An improved synthesis of cannabidiol. Tetrahedron Lett 1985;26(8):1083-1086.

(325) Mechoulam R, Brueggemeier RW, Denlinger DL. Estrogens in insects. Experientia 1984;40(9):942-944.

(326) Srebnik M, Mechoulam R. A new easy method for the synthesis of cyclic halogenoethers and halogenolactones. Journal of the Chemical Society, Chemical Communications 1984(16):1070-1071.

(327) Srebnik M, Mechoulam R. Reactions of cannabinoid tosylhydrazones. Stereochemical aspects. Tetrahedron 1984;40(19):3839-3843.

(328) Srebnik M, Lander N, Breuer A, Mechoulam R. Base-catalysed double-bond isomerizations of cannabinoids: Structural and stereochemical aspects. Journal of the Chemical Society, Perkin Transactions 1 1984:2881-2886.

(329) Edery H, Porath G, Mechoulam R, Lander N, Srebnik M, Lewis N. Activity of novel aminocannabinoids in baboons. J Med Chem 1984;27(10):1370-1373.

(330) Srebnik M, Mechoulam R. A facile method for regiospecific hydroxylation of resorcinol diethers. Synthesis 1983;1983(12):1046-1048.

(331) Mechoulam R, Lander N, Dikstein S, Shalita B. Cannabinoid drugs. Arch Toxicol 1983;53(Suppl. 6):104.

(332) Consroe P, Benedito MAC, Leite JR, Carlini EA, Mechoulam R. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 1982;83(3-4):293-298.

(333) Leite JR, Carlini EA, Lander N, Mechoulam R. Anticonvulsant effects of the (-) and (+)isomers of cannabidiol and their dimethylheptyl homologs. Pharmacology 1982;24(3):141-146.

(334) Zehavi U, Mechoulam R. O- and C-d-glucosyluronic acid derivatives of Δ1-tetrahydrocannabinol: Synthesis and differential behavior to β-glucuronidase. Carbohydr Res 1981;98(1):143-147.

(335) Järbe TUC, Swedberg MDB, Mechoulam R. A repeated tests procedure to assess onset and duration of the cue properties of (-)Δ9-THC, (-)Δ8-THC-DMH and (+)Δ8-THC. Psychopharmacology 1981;75(2):152-157.

(336) MECHOULAM R. Current Status of Therapeutic Opportunities Based on Cannabinoid Research. An Overview. J Clin Pharmacol 1981;21(1 S):2S-7S.

(337) Bialer M, El‐On J, Yagen B, Mechoulam R. Antiparasitic structure‐activity relationships of congocidine derivatives. J Pharm Sci 1981;70(7):822-824.

(338) Noam M, Tamir I, Breuer E, Mechoulam R. Conversion of ruscogenin into 1α- and 1β hydroxycholesterol derivatives. Structure elucidation by computer assisted analysis of their lanthanide-induced nmr shifts. Tetrahedron 1981;37(3):597-604.

(339) Bialer M, Yagen B, Mechoulam R, Becker Y. Structure-Activity Relationships of Pyrrole Amidine Antiviral Antibiotics. 2. Preparation of Mono-and Tripyrrole Derivatives of Congocidine. J Med Chem 1980;23(10):1144-1148.

(340) Mechoulam R, Lander N, Varkony TH, Kimmel I, Becker O, Ben-Zvi Z, et al. Stereochemical Requirements for Cannabinoid Activity. J Med Chem 1980;23(10):1068-1072.

(341) Revuelta AV, Cheney DL, Costa E, Lander N, Mechoulam R. Reduction of hippocampal acetylcholine turnover in rats treated with (-)-Δ8-tetrahydrocannabinol and its 1′,2′-dimethyl-heptyl homolog. Brain Res 1980;195(2):445-452.

(342) Tamir I, Mechoulam R, Meyer AY. Cannabidiol and Phenytoin: A Structural Comparison. J Med Chem 1980;23(2):220-223.

(343) Mechoulam R, Lander N. Cannabis: a possible source of new drugs. Pharm Int 1980;1(1):19-21.

(344) Bialer M, Yagen B, Mechoulam R. Structure elucidation of a condensation product of 4‐aminopyrrole derivatives and dicyclohexylcarbodiimide. J Heterocycl Chem 1980;17(8):1797-1798.

(345) Bialer M, Yagen B, Mechoulam R, Becker Y. Structure–activity relationships of pyrrole amidine antiviral antibiotics III: Preparation of distamycin and congocidine derivatives based on 2,5‐disubstituted pyrroles. J Pharm Sci 1980;69(11):1334-1338.

(346) Mechoulam R, Lander N, Tamir I, Ben‐Zvi Z, Kimmel Y. Base‐Catalyzed Conversion of an Equatorial into an Axial Methoxycarbonyl Group Due to a 1,5‐Long‐Range Substituent Effect. Angew Chem Int Ed Engl 1980;19(7):543-543.

(347) Cordova T, Ayalon D, Lander N, Mechoulam R, Nir I, Puder M, et al. The ovulation blocking effect of cannabinoids: Structure-activity relationships. Psychoneuroendocrinology 1980;5(1):53-62.

(348) Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21(3):175-185.

(349) Ohlsson A, Agurell S, Leander K, Dahmén J, Edery H, Porath G, et al. Synthesis and psychotropic activity of side-chain hydroxylated Δ 6-tetrahydrocannabinol metabolites. ACTA PHARM SUECICA 1979;16(1):21-33.

(350) Agurell S, Edward C, Halldin M, Leander K, Levy S, Lindgren JE, et al. Chemical synthesis and biological occurrence of carboxylic acid metabolites of Δ1(6)-tetrahydrocannabinol. Drug Metab Dispos 1979;7(3):155-161.

(351) Bialer M, Yagen B, Mechoulam R, Becker Y. Structure-Activity Relationships of Pyrrole Amidine Antiviral Antibiotics. 1. Modifications of the Alkylamidine Side Chain. J Med Chem 1979;22(11):1296-1301.

(352) Rosell S, Björkroth U, Agurell S, Leander K, Ohlsson A, Martin B, et al. Relation between effects of cannabinoid derivatives on the twitch response of the isolated guinea-pig ileum and their psychotropic properties. Adv Biosci 1978;22-23:63-70.

(353) Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften 1978;65(4):174-179.

(354) Levy S, Yagen B, Mechoulam R. Identification of a C-glucuronide of δ6- tetrahydrocannabinol as a mouse liver conjugate in vivo. Science 1978;200(4348):1391-1392.

(355) Bialer M, Yagen B, Mechoulam R. A total synthesis of distamycin a, an antiviral antibiotic. Tetrahedron 1978;34(15):2389-2391.

(356) McCallum NK, Gugelmann A, Brenninkmeijer CAM, Mechoulam R. Isotope effect studies on the dehydrogenation of Δ1-tetrahydrocannabinol in the rat. Experientia 1977;33(8):1012-1014.

(357) Goldblum A, Mechoulam R. Sodium chromate oxidation of enol benzoates. Allylic oxidation versus a novel rearrangement. J Chem Soc Perkin Trans 1 1977:1889-1898.

(358) Yagen B, Levy S, Mechoulam R, Ben-Zvi Z. Synthesis and Enzymatic Formation of a C-Glucuronide of Δ6-Tetrahydrocannabino. J Am Chem Soc 1977;99(19):6444-6446.

(359) Lander N, Mechoulam R. Formation of ortho-menthenes by acid-catalysed ring opening of pin-2-ene derivatives. Journal of the Chemical Society, Perkin Transactions 1 1976(5):484-488.

(360) Mechoulam R, Mccallum NK, Burstein S. Recent Advances in the Chemistry and Biochemistry of Cannabis. Chem Rev 1976;76(1):75-112.

(361) Meyer AY, Pasternak R, Sterling J, Lander N, Mechoulam R. Spectral effects in cyclobutane derivatives. The bathochromic-hypochromic shifts in compounds related to verbenone. Tetrahedron 1976;32(22):2805-2810.

(362) Lander N, Ben-Zvi Z, Mechoulam R, Martin B, Nordqvist M, Agurell S. Total syntheses of cannabidiol and Δ1-tetrahydrocannabinol metabolites. Journal of the Chemical Society, Perkin Transactions 1 1976(1):8-16.

(363) Carlini EA, Mechoulam R, Lander N. Anticonvulsant activity of four oxygenated cannabidiol derivatives. Res Commun Chem Pathol Pharmacol 1975;12(1):1-15.

(364) Banerjee SP, Snyder SH, Mechoulam R. Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. J Pharmacol Exp Ther 1975;194(1):74-81.

(365) Houry S, Mechoulam R, Loev B. Benzoxocin and Benzoxonin Derivatives. Novel Groups of Terpenophenols with Central Nervous System Activity. A Correction. J Med Chem 1975;18(9):951-952.

(366) Cais M, Dani S, Josephy Y, Modiano A, Gershon H, Mechoulam R. Studies of cannabinoid metabolites - a free radical immunoassay. FEBS Lett 1975;55(1-2):257-260.

(367) Mechoulam R, Luchter K, Goldblum A. New method for the oxidation of monoketones to 1,3-diketones. Synthesis 1974;1974(5):363-364.

(368) Houry S, Mechoulam R, Fowler PJ, Macko E, Loev B. Benzoxocin and Benzoxonin Derivatives. Novel Groups of Terpenophenols with Central Nervous System Activity. J Med Chem 1974;17(3):287-293.

(369) Shani A, Mechoulam R. Cannabielsoic acids. Isolation and synthesis by a novel oxidative cyclization. Tetrahedron 1974;30(15):2437-2446.

(370) Mechoulam R, Zvi ZB, Agurell S, Nilsson IM, Nilsson JLG, Edery H, et al. Δ6-Tetrahydrocannabinol-7-oic acid, a urinary Δ6-THC metabolite: Isolation and synthesis. Experientia 1973;29(10):1193-1195.

(371) Nilsson IM, Aqurell S, Nilsson JL, Ohlsson A, Lindgren JE, Mechoulam R. Metabolism of 7-hydroxy- 1(6)-tetrahydrocannabinol in the rabbit. Acta Pharm Suec 1973;10(2):97-106.

(372) Mechoulam R, Ben-Zvi Z, Varconi H, Samuelov Y. Cannabinoid rearrangements. Synthesis of Δ5-tetrahydrocannabinol. Tetrahedron 1973;29(11):1615-1619.

(373) Mechoulam R, Varconi H, Ben-Zvi Z, Edery H, Grunfeld Y. Synthesis and Biological Activity of Five Tetrahydrocannabinol Metabolites. J Am Chem Soc 1972;94(22):7930-7931.

(374) Edery H, Grunfeld Y, Porath G, Ben-Zvi Z, Shani A, Mechoulam R. Structure-activity relationships in the tetrahydrocannabinol series. Modifications on the aromatic ring and it the side-chain. Arzneimittelforschung 1972;22(11):1995-2003.

(375) Mechoulam R, Braun P, Gaoni Y, Mechoulam R, Braun P, Gaoni Y, et al. Syntheses of Δ1-Tetrahydrocannabinol and Related Cannabinoids. J Am Chem Soc 1972;94(17):6159-6165.

(376) Nilsson JL, Nilsson IM, Agurell S, Ben-Zvi Z, Mechoulam R. Synthesis of a potential urinary tetrahydrocannabinol metabolite. Acta Pharm Suec 1972;9(3):215-220.

(377) Gaoni Y, Mechoulam R, Gaoni Y, Mechoulam R. The Isolation and Structure of Δ-Tetrahydrocannabinol and Other Neutral Cannabinoids from Hashish. J Am Chem Soc 1971;93(1):217-224.

(378) Shani A, Mechoulam R. Photochemical reactions of cannabidiol. Cyclization to Δ1-tetrahydrocannabinol and other trans formations. Tetrahedron 1971;27(3):601-606.

(379) Ben-Zvi Z, Mechoulam R, Edery H, Porath G. 6β-hydroxy-Δ1-tetrahydrocannabinol synthesis and biological activity. Science 1971;174(4012):951-952.

(380) Edery H, Grunfeld Y, Ben‐Zvi Z, Mechoulam R. STRUCTURAL REQUIREMENTS FOR CANNABINOID ACTIVITY. Ann New York Acad Sci 1971;191(1):40-53.

(381) Eckstein B, Mechoulam R, Burstein SH. Identification of 5α-Androstane-3α, 17β-diol as a principal metabolite of pregnenolone in rat ovary at onset of puberty. Nature 1970;228(5274):866-868.

(382) Burstein SH, Menezes F, Williamson E, Mechoulam R. Metabolism of Δ1(6)-tetrahydro-cannabinol, an active marihuana constituent. Nature 1970;225(5227):87-88.

(383) Ben-Zvi Z, Mechoulam R, Burstein S. Identification through Synthesis of an Active∆1(6)-Tetrahydrocannabinol Metabolite. J Am Chem Soc 1970;92(11):3468-3469.

(384) Mechoulam R. Marihuana chemistry. Science 1970;168(3936):1159-1166.

(385) Shani A, Mechoulam R. A new type of cannabinoid. Synthesis of cannabielsoic acid A by a novel photo-oxidative cyclisation. Journal of the Chemical Society D: Chemical Communications 1970(5):273-274.

(386) Ben-Zvi Z, Mechoulam R, Burstein SH. Synthesis of Δ1 and Δ1(6) tetrahydrocannabinol metabolites. Tetrahedron Lett 1970;11(51):4495-4497.

(387) Mechoulam R, Shani A, Edery H, Grunfeld Y. Chemical basis of hashish activity. Science 1970;169(3945):611-612.

(388) Mechoulam R, Ben-Zvi Z. Carboxylation of resorcinols with methylmagnesium carbonate. Synthesis of cannabinoid acids. Anal Proc 1969(7):343-344.

(389) Yagen B, Mechoulam R. Stereospecific cyclizations and isomerizations of cannabichromene and related cannabinoids. Tetrahedron Lett 1969;10(60):5353-5356.

(390) Mechoulam R, Yagen B. Stereoselective cyclizations of cannabinoid 1,5 dienes. Tetrahedron Lett 1969;10(60):5349-5352.

(391) Mechoulam R, Ben-Zvi Z, Yagnitinsky B, Shani A. A new tetrahydrocannabinolic acid. Tetrahedron Lett 1969;10(28):2339-2341.

(392) Bicher HI, Mechoulam R. Pharmacological effects of two active constituents of marihuana. Arch Int Pharmacodyn Ther 1968;172(1):24-31.

(393) Mechoulam R. Tetrazolo Steroids. Isr J Chem 1968;6(6):909-916.

(394) Gaoni Y, Mechoulam R. The ISO‐Tetrahydrocannabinols. Isr J Chem 1968;6(5):679-690.

(395) Burstein S, Mechoulam R. Stereospecifically Labeled Δ1(6)-Tetrahydrocannabinol. J Am Chem Soc 1968;90(9):2420-2421.

(396) Mechoulam R, Yagnitinsky B, Gaoni Y. Stereoelectronic Factor in the Chloranil Dehydrogenation of Cannabinoids. Total Synthesis of dl-Cannabichromene. J Am Chem Soc 1968;90(9):2418-2420.

(397) Mechoulam R, Ben-Zvi Z, Gaoni Y. Hashish-XIII. On the nature of the beam test. Tetrahedron 1968;24(16):5615-5624.

(398) Crombie L, Ponsford R, Shani A, Yagnitinsky B, Mechoulam R. Hashish components. Photochemical production of cannabicyclol from cannabichromene. Tetrahedron Lett 1968;9(55):5771-5772.

(399) Mechoulam R, Gaoni Y. Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst 1967;25:175-213.

(400) Mechoulam R, Gaoni Y. The absolute configuration of δ1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 1967;8(12):1109-1111.

(401) Mechoulam R, Hirshfeld A. The synthesis of zapotidine. Tetrahedron 1967;23(1):239-242.

(402) Mechoulam R, Braun P, Gaoni Y. A Stereospecific Synthesis of (—)-Δ1- and (—)-Δ11(6)-Tetrahydrocannabinols. J Am Chem Soc 1967;89(17):4552-4554.

(403) Gaoni Y, Mechoulam R. Cannabichromene, a new active principle in hashish. Chemical Communications (London) 1966(1):20-21.

(404) Gaoni Y, Mechoulam R. Concerning the Isomerization of Δ1-to A1(6)-TetrahydrocannabinoI. J Am Chem Soc 1966;88(23):5673-5675.

(405) Gaoni Y, Mechoulam R. Hashish-VII. The isomerization of cannabidiol to tetrahydrocannabinols. Tetrahedron 1966;22(4):1481-1488.

(406) Mechoulam R, Gaoni Y. A Total Synthesis of dl-Δʹ-Tetrahydrocannabinol, the Active Constituent of Hashish. J Am Chem Soc 1965;87(24):5811.

(407) Mechoulam R, Gaoni Y. Erratum: A total synthesis of dl-Δ′-tetrahydrocannabinol, the active constituent of harnish (Journal of the American Chemical Society (1965) 87 (3274)). J Am Chem Soc 1965;87(24):5811.

(408) Mechoulam R, Gaoni Y. A Total Synthesis of dl-Δ1-Tetrahydrocannabinol, the Active Constituent of Hashish. J Am Chem Soc 1965;87(14):3273-3275.

(409) Mechoulam R, Gaoni Y. Hashish-IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 1965;21(5):1223-1229.

(410) Budzikiewicz H, Alpin RT, Lightner DA, Djerassi C, Mechoulam R, Gaoni Y. Massenspektroskopie und IHRE anwendung auf strukturelle und stereochemische probleme-LXVIII. Massenspektroskopische untersuchung der inhaltstoffe von haschisch. Tetrahedron 1965;21(7):1881-1888.

(411) Gaoni Y, Mechoulam R. The structure and synthesis of cannabigerol, a new hashish constituent. Proceedings of the Chemical Society 1964(MARCH):82.

(412) Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J Am Chem Soc 1964;86(8):1646-1647.

(413) Sondheimer F, Mechoulam R, Sprecher M. The synthesis of 10-hydroxy-10α-testosterone. Tetrahedron 1964;20(11):2473-2485.

(414) Mechoulam R, Gaoni Y. Pesticides. I. the structure of dihydronicotyrine. Recueil des Travaux Chimiques des Pays‐Bas 1963;82(12):1159-1162.

(415) Mechoulam R, Shvo Y. Hashish-I. The structure of Cannabidiol. Tetrahedron 1963;19(12):2073-2078.

(416) Mechoulam R, Danieli N, Mazur Y. The structure and synthesis of oleuropeic acid. Tetrahedron Lett 1962;3(16):709-712.

(417) Mechoulam R, Sondheimer F, Melera A, Kincl FA. The structure of zapotidine. J Am Chem Soc 1961;83(8):2022-2023.

(418) Sondheimer F, Mechoulam R, Sprecher M. 19-hydroxy-10-isotestosterone. Tetrahedron Lett 1960;1(43):38-44.

(419) Sondheimer F, Burstein S, Mechoulam R. Syntheses in the Cardiac Aglycone Field. III.1 The Conversion of a 14α- to a 14β-Hydroxy Group in the Androstane Series. The Ultraviolet Spectra of Δ15-Androsten-17-ones. J Am Chem Soc 1960;82(12):3209-3214.

(420) Sondheimer F, Mechoulam R. The Diels-Alder reaction of steroidal 20-methylene-Δ16-pregnene derivatives with maleic anhydride. J Org Chem 1959;24(1):106-107.

(421) Mechoulam R, Sondheimer F. The Wittig Reaction with Fluorenone. Formation of Cyclopropane Derivatives. J Am Chem Soc 1958;80(16):4386-4388.

(422) Sondheimer F, Mechoulam R. Further Aspects of the Wittig Reaction in the Steroid Series. 20-Dehydrocholesterol and 20-Isocholesterol. J Am Chem Soc 1958;80(12):3087-3090.

(423) Sondheimer F, Mechoulam R. Synthesis of Steroidal Methylene Compounds by the Wittig Reaction. J Am Chem Soc 1957;79(18):5029-5033.